KDA GROUP OPENS A U.S. SUBSIDIARY AND ACCELERATES THE GROWTH OF ITS MEDHERIZE SOLUTION

Executive Summary

• KDA Group Inc. announced the formation of a new U.S. subsidiary to launch its Medherize therapeutic monitoring SaaS platform in the United States beginning in 2026.
• The expansion targets the $243 billion specialty drug market, positioning KDA to capture a significant share of the growing oral oncology segment.
• Medherize is already deployed at major Quebec hospitals and will be adapted for integration with U.S. laboratory and pharmacy systems.

Key Details

• Subsidiary Launch: Official opening of a U.S. subsidiary slated for 2026 to commercialize Medherize in the United States.
• Market Opportunity: U.S. specialty drug market valued at > USD 243 billion (2023) and accounting for ~40% of prescription revenue, driven by at‑home oral oncology treatments.
• Product Overview: Medherize is a SaaS platform that improves therapeutic adherence, interprofessional coordination, and real‑world data collection for specialty oral therapies.
• Current Deployments: Already in use at Centre hospitalier universitaire de Québec – Université Laval (CHU de Québec) and Hôpital Saint‑Sacrement.
• Integration Strategy: The U.S. subsidiary will tailor Medherize to local healthcare infrastructure, including integration with American laboratory systems; builds on existing integration with Dossier Santé Québec (DSQ).
• Leadership Quote: CEO & Chairman Marc Lemieux stated the U.S. presence is “a pivotal step in our international expansion” and highlights the platform’s potential to address a major challenge in specialty oral treatment management.

Notable Quotes

“Our direct presence in the United States marks a pivotal step in our international expansion,” – Marc Lemieux, CEO & Chairman
“Medherize addresses a universal challenge: the efficient management and monitoring of specialty oral treatments… representing a major lever to showcase our technology and pharmaceutical partnerships across North America.” – Marc Lemieux